Ascentage Pharma to Start China Clinical Trial of Novel Cancer Drug

Ascentage Pharma Group, a China biopharma focused on cancer drugs with apoptosis mechanisms, received CFDA approval to begin clinical trials of a novel cancer drug candidate, APG-1387. As a new chemical entity, not previously approved in any country, APG-1387 was designated by the CFDA as a Class 1.1 drug and given priority review under the CFDA's Special Review Procedure. According to Ascentage, the drug is the first China-made molecule with an apoptosis mechanism to begin clinical trials in China. More details.... Share this with colleagues: // //